While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in ...

Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

8月21日，吉利德科学宣布以3.5亿美元全资收购CAR-T疗法开发公司Interius ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...